Analyst Price Target is $45.00
▲ +54.27% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $45.00, with a high forecast of $56.00 and a low forecast of $33.00. The average price target represents a 54.27% upside from the last price of $29.17.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in Crinetics Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.